• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Hemophilie-Symposion >Treatment with Interferon Alpha-la in Patients with Hepatitis C and Hemophilia
【24h】

Treatment with Interferon Alpha-la in Patients with Hepatitis C and Hemophilia

机译：用丙型肝炎和血友病患者治疗干扰素α-LA

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Already in 1943, Beeson observed a connection between the transfusion of blood products and the emergence of hepatitis [1]. Jaundice developed in 7 patients 1-4 months after the administration of whole blood or plasma. Further reports on the development of hepatitis in hemophilic patients were published in the mid-70s [2, 3,4]. Today it is generally accepted that the hepatitis C virus causes the majority of cases of post-transfusion hepatitis in the western world. It is responsible for most of the chronic liver disorders observed in hemophilic patients treated with clotting factor concentrates. The hepatitis C infection can be associated with replacement therapy involving clotting factor concentrates applied in the early 1970s [2,5,6].
机译：已经在1943年，培养皿观察到血液产品的输血和肝炎的出现之间的联系[1]。黄疸在施用全血或血浆后1-4个月内发育7例。进一步报告血友病患者肝炎的发展于70年代中期发表[2,3,4]。今天，普遍认为丙型肝炎病毒导致西方全球输血后肝炎病例。它负责在用凝血因子浓缩物处理的血友病患者中观察到的大多数慢性肝病症。丙型肝炎感染可以与涉及在20世纪70年代初期应用的凝血因子浓缩物的替代治疗相关[2,5,6]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号